Massimo Federico

Summary

Affiliation: University of Modena and Reggio Emilia
Country: Italy

Publications

  1. doi Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project
    Massimo Federico
    Dipartimento di Oncologia ed Ematologia, Universita di Modena e Reggio Emilia, Via del Pozzo 71, 41124 Modena, Italy
    J Clin Oncol 27:4555-62. 2009
  2. doi Cancer incidence in people with residential exposure to a municipal waste incinerator: an ecological study in Modena (Italy), 1991-2005
    Massimo Federico
    Medical Oncology II, University of Modena and Reggio Emilia, Via del Pozzo 71, Modena, Italy
    Waste Manag 30:1362-70. 2010
  3. doi R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi
    Massimo Federico
    Dipartimento di Oncologia ed Ematologia, Centro Oncologico Modenese, Clinica e di Sanità Pubblica, Universita di Modena e Reggio Emilia, Modena, Italy
    J Clin Oncol 31:1506-13. 2013
  4. pmc Breast cancer screening in women at increased risk according to different family histories: an update of the Modena Study Group experience
    Laura Cortesi
    Centro per lo Studio dei tumori familiari, Dipartimento di Oncologia ed Ematologia, Universita di Modena e Reggio Emilia, Italy
    BMC Cancer 6:210. 2006
  5. ncbi The length of treatment of aggressive non-Hodgkin's lymphomas established according to the international prognostic index score: long-term results of the GISL LA03 study
    Massimo Federico
    Dipartimento di Oncologia ed Ematologia, Universita di Modena e Reggio Emilia, Modena, Italy
    Eur J Haematol 76:217-29. 2006
  6. ncbi Prognostic relevance of serum beta2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study
    Massimo Federico
    Dipartimento di Oncologia ed Ematologia, Centro Oncologico Modenese, Universita di Modena e Reggio Emilia, Policlinico, Via del Pozzo 71, 41100 Modena, Italy
    Haematologica 92:1482-8. 2007
  7. doi ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial
    Massimo Federico
    Dipartimento di Oncologia ed Ematologia, Centro Oncologico Modenese, Universita di Modena e Reggio Emilia, Modena, Italy
    J Clin Oncol 27:805-11. 2009
  8. ncbi High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy
    Massimo Federico
    Dipartimento di Oncologia ed Ematologia, Universita di Modena e Reggio Emilia, Centro Oncologico Modenese, Via del Pozzo, 71 41100 Modena, Italy
    J Clin Oncol 21:2320-5. 2003
  9. doi Prognostic factors in low-grade non-Hodgkin lymphomas
    Massimo Federico
    Dipartimento di Oncologia ed Ematologia, Universita di Modena e Reggio Emilia, Centro Oncologico Modenese, Via del Pozzo, 71 41100, Modena, Italy
    Curr Hematol Malig Rep 4:202-10. 2009
  10. ncbi Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma
    Stefano Sacchi
    Department of Oncology and Hematology, University of Modena, Modena, Italy
    Cancer 110:121-8. 2007

Detail Information

Publications75

  1. doi Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project
    Massimo Federico
    Dipartimento di Oncologia ed Ematologia, Universita di Modena e Reggio Emilia, Via del Pozzo 71, 41124 Modena, Italy
    J Clin Oncol 27:4555-62. 2009
    ....
  2. doi Cancer incidence in people with residential exposure to a municipal waste incinerator: an ecological study in Modena (Italy), 1991-2005
    Massimo Federico
    Medical Oncology II, University of Modena and Reggio Emilia, Via del Pozzo 71, Modena, Italy
    Waste Manag 30:1362-70. 2010
    ..In conclusion, bearing in mind the intrinsic limits of the study, the results suggest that there is no detectable increase of cancer risk for people living in proximity to the Modena MWI...
  3. doi R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi
    Massimo Federico
    Dipartimento di Oncologia ed Ematologia, Centro Oncologico Modenese, Clinica e di Sanità Pubblica, Universita di Modena e Reggio Emilia, Modena, Italy
    J Clin Oncol 31:1506-13. 2013
    ..Although rituximab (R) is commonly used for patients with advanced follicular lymphoma (FL) requiring treatment, the optimal associated chemotherapy regimen has yet to be clarified...
  4. pmc Breast cancer screening in women at increased risk according to different family histories: an update of the Modena Study Group experience
    Laura Cortesi
    Centro per lo Studio dei tumori familiari, Dipartimento di Oncologia ed Ematologia, Universita di Modena e Reggio Emilia, Italy
    BMC Cancer 6:210. 2006
    ..However, screening modalities depend on the level of risk. Here we present an update of our screening programs based on risk classification...
  5. ncbi The length of treatment of aggressive non-Hodgkin's lymphomas established according to the international prognostic index score: long-term results of the GISL LA03 study
    Massimo Federico
    Dipartimento di Oncologia ed Ematologia, Universita di Modena e Reggio Emilia, Modena, Italy
    Eur J Haematol 76:217-29. 2006
    ..To compare two different schedules of two different anthracycline-containing regimens, where length of treatment is modulated according to the international prognostic index (IPI) in patients with aggressive non-Hodgkin's Lymphoma (NHL)...
  6. ncbi Prognostic relevance of serum beta2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study
    Massimo Federico
    Dipartimento di Oncologia ed Ematologia, Centro Oncologico Modenese, Universita di Modena e Reggio Emilia, Policlinico, Via del Pozzo 71, 41100 Modena, Italy
    Haematologica 92:1482-8. 2007
    ..The present study examined the influence of beta2M levels on overall survival (OS) of patients with follicular lymphoma (FL)...
  7. doi ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial
    Massimo Federico
    Dipartimento di Oncologia ed Ematologia, Centro Oncologico Modenese, Universita di Modena e Reggio Emilia, Modena, Italy
    J Clin Oncol 27:805-11. 2009
    ....
  8. ncbi High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy
    Massimo Federico
    Dipartimento di Oncologia ed Ematologia, Universita di Modena e Reggio Emilia, Centro Oncologico Modenese, Via del Pozzo, 71 41100 Modena, Italy
    J Clin Oncol 21:2320-5. 2003
    ..To determine whether high-dose therapy (HDT) with autologous stem-cell transplantation (ASCT) should be included in the initial consolidative treatment of patients with advanced, unfavorable Hodgkin's lymphoma (HL)...
  9. doi Prognostic factors in low-grade non-Hodgkin lymphomas
    Massimo Federico
    Dipartimento di Oncologia ed Ematologia, Universita di Modena e Reggio Emilia, Centro Oncologico Modenese, Via del Pozzo, 71 41100, Modena, Italy
    Curr Hematol Malig Rep 4:202-10. 2009
    ..The field of biologically specific associated parameters holds great potential but requires more research and work to produce translational results...
  10. ncbi Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma
    Stefano Sacchi
    Department of Oncology and Hematology, University of Modena, Modena, Italy
    Cancer 110:121-8. 2007
    ..The current study was conducted to asses the safety profile and clinical activity of rituximab in combination with fludarabine and cyclophosphamide in patients with recurrent follicular lymphoma (FL)...
  11. doi Outcome evaluation in pre-trastuzumab era between different breast cancer phenotypes: a population-based study on Italian women
    Laura Cortesi
    Department of Oncology and Hematology, University of Modena and Reggio Emilia, Via del Pozzo 71, Modena, Italy
    Tumori 98:743-50. 2012
    ..Our aim was to evaluate the prognosis of these phenotypes in the pre-trastuzumab era in a large cohort of Italian women...
  12. doi Distribution of second primary malignancies suggests a bidirectional effect between breast and endometrial cancer: a population-based study
    Laura Cortesi
    Dipartimento di Oncologia ed Ematologia, Universita di Modena e Reggio Emilia, Modena, Italy
    Int J Gynecol Cancer 19:1358-63. 2009
    ..The aim of this study was to investigate the incidence of second primary tumors in patients with breast cancer (BC), with particular regard to bidirectional risk for endometrial cancer (EC)...
  13. pmc Favourable ten-year overall survival in a Caucasian population with high probability of hereditary breast cancer
    Laura Cortesi
    Department of Oncology and Haematology, University of Modena and Reggio Emilia, Modena, Italy
    BMC Cancer 10:90. 2010
    ....
  14. ncbi Incidence, clinical characteristics and survival of malignant lymphomas: a population-based study from a cancer registry in northern Italy
    Stefano Luminari
    Dipartimento di Oncologia ed Ematologia, Universita di Modena e Reggio Emilia, Modena, Italy
    Hematol Oncol 25:189-97. 2007
    ..The usefulness of a population-based approach to better characterizing different lymphoma subtypes is also demonstrated...
  15. doi Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis
    Samantha Pozzi
    Programme of Innovative Therapy in Oncology and Haematology, Department of Diagnostic, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Modena, Italy
    Br J Haematol 163:40-6. 2013
    ..This observation provides circumstantial evidence that novel therapies might impact patient survival. Despite the limits of this study, these data refer to an unselected population, giving a picture of every day clinical practice...
  16. doi Monocytosis has adverse prognostic significance and impacts survival in patients with T-cell lymphomas
    Alessia Bari
    Department of Diagnostic, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Modena, Italy
    Leuk Res 37:619-23. 2013
    ..8 × 10(9)/L, hemoglobin<120 g/L, albumin<35 g/L) had a negative influence on outcome, but in multivariate analysis, monocytosis alone had a stronger association with poor OS...
  17. pmc Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based study
    Claudia Mucciarini
    Department of Oncology and Haematology, University of Modena and Reggio Emilia, Modena, Italy
    BMC Cancer 7:230. 2007
    ..This study examined the incidence of GIST in the province of Modena, including pathologic features and clinical outcome...
  18. doi Tumor size, node status, grading, HER2 and estrogen receptor status still retain a strong value in patients with operable breast cancer diagnosed in recent years
    Laura Cortesi
    Department of Oncology and Haematology, University of Modena and Reggio Emilia, Modena, Italy
    Int J Cancer 132:E58-65. 2013
    ....
  19. doi Protein expression patterns associated with advanced stage ovarian cancer
    Laura Cortesi
    Department of Oncology and Haematology, University of Modena and Reggio Emilia, Modena, Italy
    Electrophoresis 32:1992-2003. 2011
    ..Moreover, this study suggests that calgranulin expression may be used as a diagnostic and/or prognostic biomarker...
  20. doi Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study
    Stefano Sacchi
    Centro Oncologico Modenese, Policlinico, Largo del Pozzo 71, 4100 Modena Italy
    Haematologica 93:1335-42. 2008
    ..The aims of this study were to determine the incidence and time free of second cancers in this subset of patients...
  21. doi Prognosis and treatment of micrometastatic breast cancer sentinel lymph node: a population-based study
    Laura Cortesi
    Department of Oncology and Haematology, University of Modena and Reggio Emilia, Modena, Italy
    J Surg Oncol 106:399-405. 2012
    ..The purpose of this study is to determine the adequate surgical treatment and prognosis of Nmic in a population-based series of breast cancer patients...
  22. doi Identification of protein clusters predictive of response to chemotherapy in breast cancer patients
    Laura Cortesi
    Department of Oncology and Haematology, University of Modena and Reggio Emilia, Modena, Italy
    J Proteome Res 8:4916-33. 2009
    ....
  23. doi Collective evidence supports neutrality of BRCA1 V1687I, a novel sequence variant in the conserved THV motif of the first BRCT repeat
    Laura Cortesi
    Department of Oncology, Hematology and Respiratory Diseases, University of Modena and Reggio Emilia, Via del Pozzo 71, 41100, Modena, Italy
    Breast Cancer Res Treat 134:435-41. 2012
    ..Our collected evidence suggests that, although occurring in a highly conserved region, the BRCA1 V1687I variant is likely a benign sequence alteration...
  24. doi Use of 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography in patients with Hodgkin lymphoma in daily practice: a population-based study from Northern Italy
    Stefano Luminari
    Dipartimento di Oncologia ed Ematologia, Universita di Modena e Reggio Emilia, Modena, Italy
    Leuk Lymphoma 52:1689-96. 2011
    ..33); the F-PET result was the only prognostic factor for overall survival (OS) (HR 14.2). This population-based study confirms the prognostic role of I-PET for FFS also in daily practice; the results of F-PET can be used to predict OS...
  25. ncbi Estimating survival in newly diagnosed cancer patients: use of computer simulations to evaluate performances of different approaches in a wide range of scenarios
    Ivan Rashid
    Modena Cancer Registry, Department of Oncology and Hematology, University of Modena and Reggio Emilia, Modena, Italy
    Stat Med 27:2145-58. 2008
    ..The results of simulations could be useful for a quick identification of the most appropriate approach when estimating up-to-date cancer survival rates...
  26. ncbi The role of anthracyclines in follicular lymphomas
    Stefano Luminari
    Oncologia Medica II, Dipartimento di Oncologia ed Ematologia, Universita di Modena e Reggio Emilia, Centro Oncologico Modenese, Modena, Italy
    Leuk Lymphoma 47:2267-8. 2006
  27. ncbi Hodgkin's disease: a quantitative evaluation by computed tomography of tumor burden
    Pietro Torricelli
    Department of Radiology, University of Modena and Reggio Emilia, Policlinico, Via del Pozzo 71, I 41100 Modena, Italy
    Clin Imaging 28:239-44. 2004
    ..It is concluded that the CT-calculated TB is a reliable index showing good correlation with other commonly used prognostic parameters...
  28. doi Prognostic tools in follicular lymphomas
    Stefano Luminari
    Centro Oncologico Modenese, Dipartimento integrato di Oncologia, Ematologia e Malattie dell Apparato Respiratorio, Universita di Modena e Reggio Emilia, Modena, Italy
    Expert Rev Hematol 2:549-62. 2009
    ..The progressive development of new and more effective therapies for the treatment of FL makes the study of prognosis a dynamic and evolving area of clinical research...
  29. doi Lymph node evaluation in stage IIA colorectal cancer and its impact on patient prognosis: a population-based study
    Francesco Iachetta
    Department of Oncology, Hematology and Respiratory Diseases, University of Modena and Reggio Emilia, Modena, Italy
    Acta Oncol 52:1682-90. 2013
    ..The aim of this study was to assess the relationship between number of examined lymph nodes and survival in patients with stage IIA (pT3N0M0) colorectal cancer, and to determine the optimal number of lymph nodes that should be examined...
  30. doi A case of skeletal and bone marrow metastases from breast cancer treated with eribulin mesylate
    Etleva Pashaj
    Department of Oncology, Haematology and Respiratory Diseases, University of Modena and Reggio Emilia, Via del Pozzo 71, 41100, Modena, Italy
    Future Oncol 9:1437-42. 2013
    ..We report our experience with eribulin mesylate in a pancytopenic heavily pretreated patient with multiple bone metastases and bone marrow infiltration from breast cancer...
  31. pmc Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project
    Massimo Federico
    Universita di Modena e Reggio Emilia, Modena, Italy
    J Clin Oncol 31:240-6. 2013
    ..The International Peripheral T-Cell Lymphoma Project was undertaken to better understand the subtypes of T-cell and natural killer (NK) -cell lymphomas...
  32. pmc Follicular lymphoma - treatment and prognostic factors
    Stefano Luminari
    Department of Oncology, Hematology and Respiratory Diseases, L Università di Modena e Reggio Emilia UniMoRe, Modena, Italy
    Rev Bras Hematol Hemoter 34:54-9. 2012
    ..This review provides a general overview of the state of the art in the management of follicular lymphoma and also, a brief description regarding the current prognostic tools available for treatment decisions...
  33. pmc Anthracyclines: a cornerstone in the management of non-Hodgkin's lymphoma
    Stefano Luminari
    Universita di Modena e Reggio Emilia, Modena, Italy
    Hematol Rep 3:e4. 2011
    ..The use of liposomal doxorubicin in combination regimens for other conditions, such as follicular lymphoma and splenic marginal zone lymphoma, is also under investigation, and early results are promising...
  34. ncbi Prognosis of follicular lymphomas
    Stefano Luminari
    Dipartimento di Oncologia ed Ematologia, Universita di Modena e Reggio Emilia, Modena, Italy
    Hematol Oncol 24:64-72. 2006
    ..Further data and large international cooperative studies are needed to translate into clinical practice the novel acquisitions of biology and therapeutics...
  35. ncbi Prevalence and prognostic significance of sMUC-1 levels in plasma cell dyscrasias
    Stefano Luminari
    Dipartimento di Oncologia ed Ematologia, Universita di Modena e Reggio Emilia, Milan, Italy
    Br J Haematol 121:772-4. 2003
    ..49 months, P = 0.003)...
  36. pmc T-cell lymphomas in South america and europe
    Monica Bellei
    Department of Oncology, Hematology and Respiratory Diseases, L Università di Modena e Reggio Emilia UniMoRe, Modena, Italy
    Rev Bras Hematol Hemoter 34:42-7. 2012
    ..These projects are the basis of forthcoming cooperative, large scale trials to detail biologic characteristics of each sub-entity and to possibly individuate targets for new therapies...
  37. pmc Prognosis of screen-detected breast cancers: results of a population based study
    Laura Cortesi
    Dipartimento di Oncologia ed Ematologia, Universita di Modena e Reggio Emilia, Italy
    BMC Cancer 6:17. 2006
    ..However, the assessment of 5-year overall and event-free survival could represent an earlier measure of the efficacy of mammography screening program (MSP)...
  38. ncbi Splenosis peritonei
    Stefano Luminari
    Dipartimento di Oncologia ed Ematologia, Universita di Modena e Reggio Emilia, Modena, Italy
    Br J Haematol 123:378. 2003
  39. ncbi Italian family with two independent mutations: 3358T/A in BRCA1 and 8756delA in BRCA2 genes
    Laura Cortesi
    Dipartimento di Oncologia ed Ematologia, Universita di Modena e Reggio Emilia, Italy
    Eur J Hum Genet 11:210-4. 2003
    ..The discovery of the BRCA2 mutation allowed us to alert the patient's daughter who, otherwise, could be falsely reassured since she had a negative BRCA1 test...
  40. ncbi The role of anthracyclines in combination chemotherapy for the treatment of follicular lymphoma: retrospective study of the Intergruppo Italiano Linfomi on 761 cases
    Luigi Rigacci
    Cattedra e Divisione di Ematologia, Universita di Firenze, Firenze, Italia
    Leuk Lymphoma 44:1911-7. 2003
    ..On the basis of these results anthracycline-containing regimens (ACR) should be considered as the standard treatment of patients with advanced follicular lymphoma...
  41. ncbi Stage-specific incidence of breast cancer before the beginning of organized screening programs in Italy
    Eva Buiatti
    Tuscany Regional Health Agency, Florence, Italy
    Cancer Causes Control 13:65-71. 2002
    ..To measure stage-specific geographic and time variability of breast cancer in seven Italian areas before the onset of organized screening programs...
  42. ncbi Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study
    Andrea Gallamini
    Struttura Complessa Ematologia Azienda Ospedaliera S Croce e Carle, Cuneo, Italy
    Blood 103:2474-9. 2004
    ..9% and 38.8%, respectively; group 3, 2 factors, with 5-year and 10-year OS of 32.9% and 18.0%, respectively; group 4, 3 or 4 factors, with a 5-year and 10-year OS of 18.3 and 12.6%, respectively (P< or =.0001; log-rank, 66.79)...
  43. ncbi Follicular lymphoma international prognostic index
    Philippe Solal-Celigny
    Centre Jean Bernard, 9 rue Beauverger, 72000 Le Mans, France
    Blood 104:1258-65. 2004
    ..Results were very similar in the confirmation group. The FLIPI may be used for improving treatment choices, comparing clinical trials, and designing studies to evaluate new treatments...
  44. ncbi Vinblastine, bleomycin, and methotrexate chemotherapy plus irradiation for patients with early-stage, favorable Hodgkin lymphoma: the experience of the Gruppo Italiano Studio Linfomi
    Paolo G Gobbi
    Medicina Interna e Oncologia Medica, Universita di Pavia, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy
    Cancer 98:2393-401. 2003
    ..The acknowledged effectiveness of vinblastine, bleomycin, and methotrexate (VBM) chemotherapy in patients with early-stage Hodgkin lymphoma has been associated with conflicting toxicity reports...
  45. ncbi Incidence of AIDS-defining cancers after AIDS diagnosis among people with AIDS in Italy, 1986-1998
    Silvia Franceschi
    Agency for Research on Cancer, Lyon, France
    J Acquir Immune Defic Syndr 34:84-90. 2003
    ..5% in 1993-1996 to 2.4% in 1997-1998, but IRs after AIDS could not be evaluated. On account of the marked decline of KS in men in 1997-1998, the overall burden of ADCs in Italy became similar in both genders...
  46. ncbi High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: a multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in patients
    Corrado Tarella
    Dipartimento Medicina Oncologia Sperimentale, Divisione Universitaria di Ematologia, Torino, Italy
    Cancer 97:2748-59. 2003
    ....
  47. ncbi Treatment of indolent B-Cell nonfollicular lymphomas: final results of the LL01 randomized trial of the Gruppo Italiano per lo Studio dei Linfomi
    Luca Baldini
    Unità Operativa Ematologia 1, Centro G Marcora, Ospedale Maggiore, IRCCS, Via F Sforza 35, 20121 Milano, Italy
    J Clin Oncol 21:1459-65. 2003
    ..To evaluate the effect of epirubicin on therapeutic response and survival in patients with indolent nonfollicular B-cell lymphomas (INFL) treated with pulsed high-dose chlorambucil...
  48. ncbi Bleomycin, epidoxorubicin, cyclophosphamide, vincristine and prednisone (BACOP) in patients with follicular non-Hodgkin's lymphoma: results of a prospective, multicenter study of the Gruppo Italiano Per Lo Studio Dei Linfomi (GISL)
    Marco Lombardo
    Dipartimento di Oncologia, Azienda Ospedaliera Santo Spirito, Pescara, Italy
    Leuk Lymphoma 43:1795-801. 2002
    ..In particular the BACOP schedule is a valid anthracycline-containing regimen, and in this respect suitable to be considered as a treatment option...
  49. ncbi Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients
    Pier Luigi Zinzani
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Italy
    Haematologica 87:1258-64. 2002
    ....
  50. ncbi Lymphomas: Hodgkin and non-Hodgkin lymphomas
    Massimo Federico
    Registro tumonr della Provincia di Modena
    Epidemiol Prev 28:92-6. 2004
    ..As regards non-Hodgkin lymphomas (16, 470 incident cases and 7,193 deaths), there is a significant increasing trend, in both sexes, both for incidence (more than 3 %/years) and mortality (about 2%/year)...
  51. ncbi MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors
    Paolo G Gobbi
    Medicina Interna, Oncologia e Gastroenterologia, Universita di Pavia, IRCCS, Policlinico San Matteo, Piazzale Golgi no 2, 27100 Pavia, Italy
    Clin Cancer Res 12:529-35. 2006
    ..Late results, toxicity, and second tumor incidence were reviewed in all the patients treated...
  52. ncbi Vinorelbine, gemcitabine, procarbazine and prednisone (ViGePP) as salvage therapy in relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL): results of a phase II study conducted by the Gruppo Italiano per lo Studio dei Linfomi
    Nicola Di Renzo
    Unità Operativa di Ematologia ed Oncologia Medica, C R O B, Ospedale Oncologico Regionale, Rionero in Vulture, PZ, Italy
    Leuk Lymphoma 47:473-9. 2006
    ..This regimen should be tested in less heavily pre-treated patients and probably in combination with new active agents such Rituximab. Further developments of this combination are warranted...
  53. ncbi Splenic marginal zone lymphoma: a prognostic model for clinical use
    Luca Arcaini
    Division of Hematology, IRCCS Policlinico San Matteo, University of Pavia, 27100 Pavia, Italy
    Blood 107:4643-9. 2006
    ..In conclusion, with the use of readily available factors, this prognostic index may be an effective tool for evaluating the need for treatment and the intensity of therapy in an individual patient...
  54. ncbi Role of interferon-alpha administration after 2-deoxycoformycin in the treatment of hairy cell leukemia patients
    Giuseppe Marotta
    Hematology Unit, University of Siena, Siena, Italy
    Eur J Haematol 77:109-13. 2006
    ....
  55. ncbi Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis
    Carlo Visco
    Department of Hematology, Ospedale S Bortolo, Vicenza, Italy
    Eur J Haematol 77:387-94. 2006
    ..To evaluate the prognostic role of pretreatment serum levels of soluble CD30 (sCD30) in patients with advanced stage classical Hodgkin's lymphoma (cHL) treated with adriamycin, bleomycin, vinblastine, and dacarbazine or equivalent regimens...
  56. ncbi ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi
    Paolo G Gobbi
    Medicina Interna e Oncologia Medica, Universita di Pavia, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico S Matteo, Pavia, Italy
    J Clin Oncol 23:9198-207. 2005
    ....
  57. ncbi High dose sequential chemotherapy with autologous transplantation versus dose-dense chemotherapy MegaCEOP as first line treatment in poor-prognosis diffuse large cell lymphoma: an "Intergruppo Italiano Linfomi" randomized trial
    Umberto Vitolo
    Ematologia, Azienda Ospedaliera S Giovanni Battista, Corso Bramante 88, 10126 Turin, Italy
    Haematologica 90:793-801. 2005
    ....
  58. ncbi Revised response criteria for malignant lymphoma
    Bruce D Cheson
    Division of Hematology Oncology, Georgetown University Hospital, Washington, DC, USA
    J Clin Oncol 25:579-86. 2007
    ..Standardized response criteria are needed to interpret and compare clinical trials and for approval of new therapeutic agents by regulatory agencies...
  59. ncbi National estimates of cancer patients survival in Italy: a model-based method
    Riccardo Inghelmann
    Centro Nazionale di Epidemiologia, Sorveglianza e Promozione della Salute, Reparto di Epidemiologia dei Tumori, Istituto Superiore di Sanita, Rome, Italy
    Tumori 91:109-15. 2005
    ..Moreover, to measure the degree of representativeness of cancer patient survival obtained from Italian cancer registries data...
  60. ncbi Quality of life assessment in elderly patients with aggressive non-Hodgkin's Lymphoma treated with anthracycline-containing regimens. Report of a prospective study by the Intergruppo Italiano Linfomi
    Francesco Merli
    Unità Operativa di Ematologia, Ospedale S Maria Nuova, Reggio Emilia, Italy
    Haematologica 89:973-8. 2004
    ..The aim of this study was to evaluate quality of life (QOL) in a group of elderly patients (> 65 years) with aggressive non-Hodgkin's lymphoma (NHL) treated with chemotherapy regimens containing anthracyclines...
  61. ncbi In situ breast cancer: incidence trend and organised screening programmes in Italy
    Alessandro Barchielli
    Epidemiology Unit, Local Health Unit 10, Via di San Salvi 12, 50135 Florence, Italy
    Eur J Cancer 41:1045-50. 2005
    ..Therefore, the effect of mammography on stage-specific incidence of CIS may be more marked than expected on the basis of the effect of screening programmes...
  62. ncbi Estimated and observed cancer incidence in Italy: a validation study
    Riccardo Capocaccia
    Reparto di Epidemiologia dei Tumori, Centro Nazionale di Epidemiologia, Sorveglianza e Promozione della Salute, Istituto Superiore di Sanita, Rome, Italy
    Tumori 93:387-91. 2007
    ....
  63. ncbi Changes in breast cancer incidence and stage distribution in Modena, Italy: the effect of a mammographic screening program
    Daniela Turchetti
    Cattedra e Divisione di Oncologia Medica, Policlinico di Modena, Italy
    Cancer Causes Control 13:729-34. 2002
    ..Assessing changes in breast cancer (BC) incidence and stage distribution in the District of Modena, Italy, during the period 1992-1998, and their relationship to a mammographic screening program launched in 1995...
  64. doi A multicenter retrospective clinical study of CD5/CD10-negative chronic B cell leukemias
    Maria Goldaniga
    UO Ematologia e Centro Trapianti di Midollo, Ospedale Maggiore, IRCCS, University of Milan, Milan, Italy
    Am J Hematol 83:349-54. 2008
    ....
  65. ncbi Prospective study of indolent non-follicular non-Hodgkin's lymphoma: validation of Gruppo Italiano per lo studio dei linfomi (GISL) prognostic criteria for watch and wait policy
    Fortunato Morabito
    Centro Trapianti di Midollo Osseo, Dipartimento di Ematologia, Azienda Ospedaliera Bianchi Melacrino Morelli Via Melacrino, 89100 Reggio Calabria, Italy
    Leuk Lymphoma 43:1933-8. 2002
    ..In conclusion, the GISL definition of indolent disease is a reliable tool to design the appropriate therapeutic strategy in this histological setting...
  66. ncbi Incidence of primary liver cancer in Italy between 1988 and 2002: an age-period-cohort analysis
    Luigino Dal Maso
    Epidemiology and Biostatistics Unit, Aviano Cancer Center, IRCCS, Via Franco Gallini 2, 33081 Aviano PN, Italy
    Eur J Cancer 44:285-92. 2008
    ..Incidence of PLC over the last two decades in Italy did not substantially change but huge geographical variability emerged, mainly due to different times and modalities of spread of hepatitis C virus...
  67. ncbi Prevalence of BRCA1 genomic rearrangements in a large cohort of Italian breast and breast/ovarian cancer families without detectable BRCA1 and BRCA2 point mutations
    Simona Agata
    Department of Oncology and Surgical Sciences, Oncology Section, University of Padua, Padua, Italy
    Genes Chromosomes Cancer 45:791-7. 2006
    ..11 < 0.19 < 0.28) of the BRCA1 mutation positive families. We conclude that the search for major genomic rearrangements is essential for an accurate and comprehensive BRCA1 mutation detection strategy in Italy...
  68. ncbi Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer
    Maurie Markman
    University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Gynecol Oncol 103:195-8. 2006
    ..The relationship between survival and early changes in the serum level of the CA-125 antigen in patients with advanced ovarian cancer remains poorly defined...
  69. ncbi Different expressivity of BRCA1 and BRCA2: analysis of 179 Italian pedigrees with identified mutation
    Paolo Aretini
    Section of Oncogenetics, Division of Surgical, Molecular and Ultrastructural Pathology, Department of Oncology, University of Pisa, Pisa, Italy
    Breast Cancer Res Treat 81:71-9. 2003
    ..Proportion of ovarian cancer was increased in the 5' portion of BRCA1, and presence of prostate or pancreatic cancer in a family was correlated with presence of ovarian cancer in BRCA2...
  70. ncbi Breast carcinoma survival in Europe and the United States
    Milena Sant
    Epidemiology Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Cancer 100:715-22. 2004
    ..Breast carcinoma survival rates were found to be higher in the U.S. than in Europe...
  71. ncbi [Cancer incidence in Modena: 2002-2006 projections]
    Antonella Fracca
    Registro tumori della Provincia di Modena
    Epidemiol Prev 30:114-9. 2006
    ..Cancer incidence predictions for the period 2002-2006 in the Province of Modena applying a Bayesian APC (Age Period Cohort) model...
  72. ncbi Clinical relevance of immunophenotype in a retrospective comparative study of 297 peripheral T-cell lymphomas, unspecified, and 496 diffuse large B-cell lymphomas: experience of the Intergruppo Italiano Linformi
    Fortunato Morabito
    Centro Trapianti Midollo Osseo, Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy
    Cancer 101:1601-8. 2004
    ..To assess the impact of T-cell/B-cell phenotype on clinical outcome, the authors retrospectively compared patients who had peripheral T-cell lymphoma, unspecified (PTCL-U), with patients who had diffuse large B-cell lymphoma (DLBCL)...
  73. ncbi Cancer incidence in eastern Libya: the first report from the Benghazi Cancer Registry, 2003
    Mufid El Mistiri
    Benghazi Cancer Registry, Department of Oncology and Hematology, Garyounis University, Benghazi, Libya
    Int J Cancer 120:392-7. 2007
    ....
  74. ncbi Multicenter comparative multimodality surveillance of women at genetic-familial high risk for breast cancer (HIBCRIT study): interim results
    Francesco Sardanelli
    University of Milan School of Medicine, Department of Medical and Surgical Sciences, Unit of Radiology, IRCCS Policlinico San Donato, Via Morandi 30, 20097 San Donato Milanese, Milan, Italy
    Radiology 242:698-715. 2007
    ....
  75. doi ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project
    Kerry J Savage
    Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada
    Blood 111:5496-504. 2008
    ..Although the prognosis of ALK(-) ALCL appears to be better than that for PTCL-NOS, it is still unsatisfactory and better therapies are needed. Primary cutaneous ALCL is associated with an indolent course...